Ramucirumab + Erlotinib for Lung Cancer
(RELAY Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug combination to treat patients with advanced lung cancer who have specific genetic changes. The treatment aims to stop cancer growth by cutting off its blood supply and blocking growth signals. One of the drugs being tested has shown significant survival benefits when combined with other treatments in advanced lung cancer.
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for people with a specific type of advanced lung cancer (Stage IV NSCLC) that has not been treated before and has certain EGFR mutations. Participants must have a life expectancy of at least 3 months, one measurable lesion, and provide tissue samples. It's not for those with certain medical conditions like significant bleeding disorders or recent major blood vessel invasion by cancer.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Erlotinib (Tyrosine Kinase Inhibitor)
- Gefitinib (Tyrosine Kinase Inhibitor)
- Osimertinib (Tyrosine Kinase Inhibitor)
- Placebo (Other)
- Ramucirumab (Monoclonal Antibodies)
Erlotinib is already approved in Canada for the following indications:
- Non-small cell lung cancer
- Pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University